Important Information for Geron Corporation Investors: Rosen Law Firm Reminds of Upcoming Deadline
New York, NY, March 31, 2025 – Rosen Law Firm, a global investor rights law firm, alerts purchasers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024, and February 25, 2025 (the “Class Period”), to take note of the upcoming May 12, 2025 lead plaintiff deadline. Investors who wish to act as lead plaintiff in this class action must file their motion with the court no later than May 12, 2025.
Background on Geron Corporation
Geron Corporation is a clinical-stage biotechnology company focused on the development and commercialization of therapeutics for aging and age-related diseases. The company’s most advanced program is the development of Imetelstat, a first-in-class epigenetic enzyme inhibitor, for the treatment of myelofibrosis and other bone marrow failures.
Allegations Against Geron Corporation
The lawsuit alleges that Geron Corporation made materially false and misleading statements regarding the company’s business, operational, and financial results. Specifically, the lawsuit alleges that Geron Corporation failed to disclose that: (i) the clinical data for Imetelstat was insufficient to support regulatory approval, (ii) the company was experiencing delays in its clinical trials, and (iii) the company’s financial condition was weaker than represented.
Impact on Individual Investors
If you purchased Geron Corporation securities during the Class Period, you may be eligible to recover your losses, as a result of Geron Corporation’s misrepresentations and/or omissions, under the Securities Act of 1933. The lead plaintiff will act on behalf of all other class members in managing the litigation. If you wish to join the litigation as a lead plaintiff, or wish to learn more about the case, please contact attorney Thomas G. Rosen, of Rosen Law Firm, at 212-614-5450 or [email protected].
Impact on the World
The implications of this lawsuit extend beyond Geron Corporation’s investors. The biotechnology industry as a whole could face increased scrutiny and skepticism from investors and regulators. The outcome of this case could set a precedent for how other biotech companies handle clinical trial data and disclose financial information to investors.
Conclusion
Rosen Law Firm encourages investors to carefully consider their options before the May 12, 2025 lead plaintiff deadline. The firm’s dedicated securities litigation team is actively investigating the alleged securities laws violations by Geron Corporation. The firm is committed to ensuring that all investors receive the compensation they are entitled to as a result of any securities law violations. For more information, please contact Thomas G. Rosen or the Rosen Law Firm.
- Rosen Law Firm: A global investor rights law firm
- Geron Corporation: A clinical-stage biotechnology company
- Class Period: February 28, 2024, to February 25, 2025
- Lead Plaintiff Deadline: May 12, 2025
- Allegations: Materially false and misleading statements
- Impact: Potential recovery for investors; increased scrutiny for biotech industry
